List of Vtama drug patents
Vtama is owned by Dermavant Sci.
Vtama contains Tapinarof.
Vtama has a total of 4 drug patents out of which 0 drug patents have expired.
Vtama was authorised for market use on 23 May, 2022.
Vtama is available in cream;topical dosage forms.
Vtama can be used as topical treatment of plaque psoriasis in adults.
Drug patent challenges can be filed against Vtama from 2026-05-23.
The generics of Vtama are possible to be released after 13 November, 2038.
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These patents protects the active chemical substance. Only patent owner can launch products that use this active substance. | ||||
| US10647649 | DERMAVANT SCI | Process for preparing tapinarof |
Nov, 2038
(15 years from now) | |
| These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US10426743 | DERMAVANT SCI | Topical pharmaceutical compositions |
May, 2036
(13 years from now) | |
| US11458108 | DERMAVANT SCI | NA |
May, 2036
(13 years from now) | |
| US10195160 | DERMAVANT SCI | Topical pharmaceutical compositions |
May, 2036
(13 years from now) | |
| Exclusivity | Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity (NCE) | May 23, 2027 |
Drugs and Companies using TAPINAROF ingredient
NCE-1 date: 2026-05-23
Market Authorisation Date: 23 May, 2022
Treatment: Topical treatment of plaque psoriasis in adults
Dosage: CREAM;TOPICAL
VTAMA family patents
14
United States
6
Japan
3
Israel
3
Australia
3
China
3
European Union
2
Mexico
2
Singapore
2
Brazil
2
Colombia
2
Korea, Republic of
2
Chile
2
Canada
1
South Africa
1
Denmark
1
IB
1
Jordan
1
Slovenia
1
Russia
1
Hong Kong
1
Lithuania
1
Hungary
1
Morocco
1
Philippines
1
Uruguay
1
Costa Rica
1
Argentina
1
Croatia
1
Portugal
1
Spain
1
Dominican Republic
1
Poland
1
Peru
1
Taiwan, Province of China
1
RS
1
Ukraine
1
EA
900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight
Join them to stay ahead in capturing the next drug going generic